European shares fell for the second day in a row on Tuesday, with health stocks hit by a drop in their US counterparts, although battered miner Glencore halted a slide in its share price.
German carmaker Volkswagen, which has been hit by an emissions data scandal, also remained under pressure with its shares falling by nearly 2%.
The pan-European FTSEurofirst 300 index and the euro zone's blue-chip Euro STOXX 50 index both fell by around 1%, following on from losses of more than 2% on both indexes on Monday.
The STOXX Europe 600 Health Care index was among the worst-performing equity sectors, weakening by 2.1% after US pharmaceutical and biotech stocks fell overnight.
The US biotech sector was hit after US Democratic lawmakers on Monday attacked "massive" price increases of two heart drugs from Valeant Pharmaceuticals.
In Europe, British healthcare group Shire was down by 3.6% while Switzerland's BB Biotech retreated 2.8%.
"The momentum is to the downside for those biotech stocks," said Terry Torrison, managing director at Monaco-based McLaren Securities. "These are still very nervous markets, and I think that any rebound should be sold into."
BROKERS TALK UP GLENCORE
Shares in Volkswagen also fell, with Hungary's Economy Minister Mihaly Varga saying on Tuesday that about 2 million of the 11 million diesel engines involved in the Volkswagen emissions scandal were manufactured at an Audi plant in western Hungary.
The plight of Volkswagen partly led brokerage Kepler Cheuvreux to cut its rating on the German stock market to "underweight" from "neutral".
Germany's DAX hit a record high of 12,390.75 points in April but has since lost ground and is now some 24% below those levels.
The DAX and other world stock markets have lost ground in the last few months partly due to signs of a slowdown in China, which has also hit the commodity sector since China is a major consumer of metals and oil.
The prolonged fall in metals prices has been one of the reasons behind Glencore's stock market slump. It fell nearly 30% on Monday but recovered slightly to rise by 7% on Tuesday.
Analysts at US bank Citigroup said Glencore should even consider going private via a management buyout if the market rout continued, and Citi kept a "buy" rating on Glencore shares.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
)